Showing 2911-2920 of 3039 results for "".
- TopiVert Announces First Patients Dosed in THEIA-1 Phase 2b/3 Study of Dry Eye Disease Treatmenthttps://modernod.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/TopiVert Pharma announced that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1 is a multicenter, randomised, double-masked, pl
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- Heidelberg OCT2 Module Successfully Installed at the International Space Stationhttps://modernod.com/news/heidelberg-oct2-module-successfully-installed-at-the-international-space-station/2476295/Heidelberg Engineering announced that its Spectralis imaging platform with the company’s next-generation OCT2 Module has been successfully installed at the International Space Station (ISS) and is now fully operational. NASA launched the Spectralis with OCT2 Module to the ISS aboard the An
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)
- Graybug Vision Appoints Frédéric Guerard as Chief Executive Officerhttps://modernod.com/news/graybug-vision-appoints-frederic-guerard-as-chief-executive-officer/2476318/Graybug Vision announced that the board of directors has appointed Frédéric Guerard as Chief Executive Officer. Mr. Guerard’s career in the pharmaceutical industry spans over 20 years and includes multiple leadership, strategic, and commercial roles. He joins from Novartis, where he was pr
- Galimedix Therapeutics Presents Data for Investigational Eyedrops Containing GAL-101https://modernod.com/news/galimedix-therapeutics-presents-data-for-investigational-eyedrops-containing-gal-101/2476320/Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which in animal models caused sustained prevention of misfolded amyloid beta mol
- EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-yutiq/2476328/EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- Nicox Announces FDA Acceptance of Investigational NDA for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-fda-acceptance-of-investigational-nda-for-ncx-4251-phase-2-trial-in-blepharitis/2479597/Nicox SA announced that the FDA has completed its review of the company’s investigational new drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the fi